Biotech Values

[microcapfun]

Geron

>>I'm just saying that even without a buyout that I think the stock will go a good deal higher from current levels.<<

On what basis do you say that? Not discounted cash flow IMO, because they have only two products in the clinic, one which has apparently failed and the other which is patient-specific and not going to be developed further - according to the company. So there is no reason to expect any significant revenue (let alone profits) for at least a decade. Why in the world should they be valued more than cash?

In this market - once there is dissipation of the near-term hype from the loosened restrictions on hESC NIH funding (which could hurt Geron more than help it) - they could easily trade at half cash. That would be about $1/share.

That's not a prediction ...

micro